<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226902</url>
  </required_header>
  <id_info>
    <org_study_id>Interactedd</org_study_id>
    <nct_id>NCT00226902</nct_id>
  </id_info>
  <brief_title>Vascular Reactivity in Kidney Disease Patients</brief_title>
  <official_title>Integrated Studies in Vascular Reactivity and Anaemia Correction Therapy in Endstage Kidney Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Melbourne Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dialysis patients suffer from many problems with blood vessels and this is even more so for&#xD;
      patients with the added complication of diabetes. Diabetics have a number of reasons for&#xD;
      vascular disease and one of the new areas of research is looking at the cells that line the&#xD;
      blood vessels, called endothelial cells. It is thought that the number of red blood cells in&#xD;
      the blood (haemoglobin concentration) affects the function of these cells. There is very&#xD;
      little information available on what haemoglobin level is best for dialysis patients. As&#xD;
      diabetics account for almost 40% of dialysis patients worldwide it is important to understand&#xD;
      the effect different haemoglobin levels will have on the blood vessels.&#xD;
&#xD;
      Hypothesis: Endothelial cell function and the related expansile capacity of blood vessels are&#xD;
      affected by different haemoglobin concentrations [Hb] in dialysis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is going to ask dialysis patients (both diabetic and non-diabetic) to undergo a&#xD;
      series of tests at three different time points over a one year period: a baseline set of&#xD;
      tests, tested when haemoglobin is maintained at 130-140g/L and repeat the tests when&#xD;
      haemoglobin is maintained at 105-115g/L. The current recommendation for haemoglobin is&#xD;
      110-120g/L. Patients will not be required to take any study medication but a specialist&#xD;
      kidney doctor, using their usual medications of iron and erythropoietin therapy, will change&#xD;
      their haemoglobin levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pulse wave velocity at the three different haemoglobin levels</measure>
  </primary_outcome>
  <enrollment>15</enrollment>
  <condition>Kidney Failure, Chronic</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Changing hemoglobin concentration</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-80 years&#xD;
&#xD;
          2. Patients receiving either conventional haemodialysis 3-4 x week, for a duration of &gt; 6&#xD;
             months or peritoneal dialysis for a duration &gt;6 months&#xD;
&#xD;
          3. Stable dialysis access for at least 3 months (Permcath / PTFE / AVF)&#xD;
&#xD;
          4. On erythropoietin and iron therapy, with stable [Hb] x 2 months (105 - 135g/L)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uncontrolled BP: requiring dry weight or medication changes within 4 weeks prior to&#xD;
             study&#xD;
&#xD;
          2. Patients with dysrhythmias&#xD;
&#xD;
          3. Pre dialysis SBP&gt; 180 mmHg on &gt; 2 times within a 2 week period&#xD;
&#xD;
          4. Between dialysis weight gain &gt; 5% of body weight (if evident &gt; 2 times/ 2 week period)&#xD;
&#xD;
          5. Soft tissue ulcers&#xD;
&#xD;
          6. Non traumatic amputations&#xD;
&#xD;
          7. Unstable cardiac function: ischaemic or non ischaemic events requiring modification of&#xD;
             therapy, or admission to hospital within 3 months of study start: according to&#xD;
             clinical discretion&#xD;
&#xD;
          8. Planned operative procedures within 6 months of study start (including Transplant,&#xD;
             CABG, PTCA, vascular surgery)&#xD;
&#xD;
          9. Dementia&#xD;
&#xD;
         10. Clinical inability to comply with testing&#xD;
&#xD;
         11. Malignancy (active / under treatment)&#xD;
&#xD;
         12. Known hypo-responsiveness to ERT (&gt;200U/kg/wk)&#xD;
&#xD;
         13. Evidence of chronic gastrointestinal bleeding&#xD;
&#xD;
         14. Inadequate dialysis (PRU &lt; 65% or KT/V &lt; 1.2)&#xD;
&#xD;
         15. Participation in investigational study within last 3 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence P McMahon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2005</study_first_posted>
  <last_update_submitted>May 4, 2015</last_update_submitted>
  <last_update_submitted_qc>May 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2015</last_update_posted>
  <keyword>Diabetes</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Vascular reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

